Drug intelligence / Profile preview

Saltikva + FOLFIRINOX

Development stage: Unknown
Lead developer: Salspera
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
Administration: Oral, Intravenous

Overview

Saltikva + FOLFIRINOX is a combination regimen for treating advanced pancreatic cancer. It unites **Saltikva** (an orally administered, attenuated strain of *Salmonella typhimurium* genetically engineered to express human interleukin-2) with **FOLFIRINOX** (a chemotherapy protocol combining folinic acid, fluorouracil, irinotecan, and oxaliplatin). Saltikva acts primarily by stimulating immune-mediated antitumor activity in the tumor microenvironment through local delivery of IL-2, producing a surge in natural killer (NK) cell activity. FOLFIRINOX exerts cytotoxic antineoplastic effects via multiple mechanisms targeting DNA synthesis, cellular replication, and microtubule dynamics. In Phase 2 clinical studies in metastatic stage IV pancreatic cancer, this combination nearly doubled median overall survival over FOLFIRINOX alone, with no serious toxicities attributed to Saltikva.

Other names: Salmonella-IL2 + FOLFIRINOX

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on Saltikva + FOLFIRINOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saltikva + FOLFIRINOX.

Explore the full profile